Genmab — Juli 2017

[JKY_VH]

luk i dagens højeste kurs 1389

[bibob]

Dejligt at se at Dara bliver brugt i flere og flere indikationer. Måske lidt i piskefløden til jordbærrene, og vips. - overbelægninger på sygehusene er fortid.

[JKY_VH]

Fedt:-)

[flottenschmecker]

se pkt 4 - her er lidt flavor på markedsstørrelse - http://www.regioner.dk/media/5214/dara-mini-mtv-bor-dex.pdf

[flottenschmecker]

og så kommer dara+len+dex oven i hatten, men jeg kan ikke lige finde KRIS dokumentaet på castor comboen

[JKY_VH]

NBI +1,39%, det må godt smitte af i morgen.

[dohk]

U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its Keytruda in combination with other medicines for the blood cancer after more deaths were reported in patients receiving the Merck immunotherapy.
https://finance.yahoo.com/news/fda-puts-hold-merck-multiple-213905828.html

[dohk]

ser ikke ud til Pd1 inhibitorer får en plads en i behandling af MM

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[JKY_VH]

God morgen:-)

[E_L]

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers http://ir.celgene.com/releasedetail.cfm?ReleaseID=1032240

[GeorgeBest]

Nature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC MUTANOME http://www.4-traders.com/news/Nature-Publication-Reports-Favorable-Clinical-Trial-Results-of-BioNTech-s-Individualized-Cancer-Vacc--24703913/

[bibob]

That doesn't have anything to doo with Genmab, - has it. ?? E L.

[E_L]

no, not directly, just wanted to show there are still plenty companies thinking PD1 inhibitor
is usefull

[Bulder]

Vi har vel heller ikke hørt dårligt (endnu) om nivolumab, som kører i et kombistudie med dara i bl.a. MM?

[Bulder]

Kunne det tænkes at problemet ligger specifikt i Keytruda?

[E_L]

sure, or or maybe even Keytruda in that specific combo only. time will tell.

[Jedi]

I agree. The current problems of Keytruda are limited to MM. All Keytruda trials outside MM continue at full speed and PD-1 / PD-L1 agents are still considered very successful in solid tumors

[Jedi]

The new Celgene collaboration on PD-1 is also targeting solid tumors and not MM